RxDoctor Payments Data

Gloria Canizales, DO

Family Medicine · Hamburg, NJNPI 1295173185

Payments from drug & device makers

$160in general payments, 2019–2025

Across 12 payments — averaging $13.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$45
  • Amarin Pharma, Inc.$27
  • Merck$14
  • Currax Pharmaceuticals LLC$13
  • Boehringer Ingelheim$13
  • Takeda Pharmaceuticals U.S.A., Inc.$12
  • plus $35 from 3 others

What the payments were for

  • Food & beverage$14993%
  • Education$127%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$160 in reported general payments places this provider in the 30th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$246,974
Medicare patients
460
Services billed
2,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol101$125,604
OzempicSemaglutide68$83,649
JanuviaSitagliptin Phosphate61$79,976
JardianceEmpagliflozin42$52,989
TradjentaLinagliptin30$25,291
EliquisApixaban19$24,532
MounjaroTirzepatide19$23,524
TrulicityDulaglutide22$23,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,289
JanumetSitagliptin Phos/Metformin Hcl17$15,305
Breo ElliptaFluticasone/Vilanterol18$13,332
VascepaIcosapent Ethyl15$12,034
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,255
LinzessLinaclotide14$6,983
DiovanValsartan12$6,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$12$125,604101 claims
MerckJanuvia, Janumet$14$95,28178 claims
Novo NordiskOzempic$45$83,64968 claims
Boehringer IngelheimJardiance, Tradjenta$13$78,28172 claims
Lilly USA, LLCMounjaro, Trulicity$12$47,04241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Hamburg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →